Clopiodgrel-01 (Clopidogrel 75mg Apotex 1)
Clopidogrel Tablet, Film Coated
Product Images NDC 0615-8014
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 0615-8014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Clopidogrel Tebs 75mg Bingo Label (Clopidogrel 75mg Apotex 10)
This is a description for a medication packaging for Clopidogrel tablets. The tablets come in a bottle that should be stored at 20-25°C and protected from moisture. Each tablet contains 97,875 mg of Clopidogrel Bisulfate, which is equivalent to 75 mg of Clopidogrel base. The package includes a package insert binder for dosage information. The manufacturer is Apotex and it is packaged by Vangard. The lot number is included in the package and the overall configuration of the package is a trademark of Omnicare, Inc.*
Clopidogrel Tabs 75mg Unit-dose Label (Clopidogrel 75mg Apotex 11)
This is a label of Clopidogrel Tablets USP, 75 mg, manufactured by Apotex. Each tablet contains 57,875 mg of clopidogrel bisulfite/78 mg of clopidogrel base. It is for institutional use only and must be stored at 20°- 25°C (68% - 77°F), protected from moisture.*
Figure-01 (Clopidogrel 75mg Apotex 2)
This is a figure showing the effect of different proton pump inhibitors (PPIs) on the exposure of active metabolite of Clopidogrel following multiple doses of Clopidogrel 75 mg alone or with PPIs. The figure presents mean and 90% confidence interval of the effect of different PPIs including Dextansoprazole, Lansoprazole, Pastoprazole, and Omeprazole on the active metabolite AUC. The X-axis represents the timepoints while the Y-axis represents the change relative to Clopidogrel administered alone.*
Figure2 (Clopidogrel 75mg Apotex 3)
The figure shows the cumulative event rate of cardiovascular death, myocardial infarction, and stroke in the CURE study. The event rate is expressed in percentage and is compared between placebo (with aspirin) and clopidogrel (with aspirin) treatments. Other standard therapies were also used. The study followed up for several months, as indicated in the X-axis. The difference in event rate between the two treatments was statistically significant (P=0.00009).*
Figure-03 (Clopidogrel 75mg Apotex 4)
Figure3: Hazard Ratio is a statistical term used to measure the likelihood of an event occurring in one group compared to the probability of it occurring in another group. The table presented here provides data from the CURE study on various patient baseline characteristics and on-study concomitant medications or interventions. However, due to errors, the text could not be completely readable.*
Figure4 (Clopidogrel 75mg Apotex 5)
The text contains the description of Figure 4 which shows cumulative event rates for death in the COMMIT Study. The figures display the percentages of deaths before and after a proportional reduction, with a P-033 value of 7%. There is an additional note indicating that all included patients received treatment, but the rest of the data is not available.*
Figure5 (Clopidogrel 75mg Apotex 6)
This is a figure from the COMMIT study demonstrating the cumulative event rates for the combined endpoint of re-infarction, stroke, or death. The study included a placebo group with 10.1% of participants experiencing the combined endpoint and a group treated with clopidogrel with 8.2% experiencing the combined endpoint, resulting in a proportional risk reduction of 9%. The endpoints were assessed up to 28 days after randomization, and all participants received aspirin.*
Figure6 (Clopidogrel 75mg Apotex 7)
This is a report on the effects of adding clopidogrel to aspirin on the combined primary endpoint across different concomitant medication subgroups for a study called COMMIT. There is also information regarding baseline counts, categories, and some values. The report mentions three prognostic index groups that were based on absolute risk of primary composite outcome for each patient that were calculated from baseline prognostic variables using a Cox regression model.*
Figure7 (Clopidogrel 75mg Apotex 8)
Figure8 (Clopidogrel 75mg Apotex 9)
The text provides a figure (Figure 8) with a graph showing the cumulative rate of fatal or non-fatal vascular events during the course of the CAPRIE study. The study involved the use of clopidogrel, a medication used to prevent blood clots, and followed patients for up to 80 months.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
